The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3b safety study of fixed-dose durvalumab + tremelimumab or durvalumab monotherapy in advanced solid malignancies (STRONG): Urothelial and non-urothelial urinary tract carcinoma module A.
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Amgen; Argos Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Janssen; Merck; Novartis; Pfizer; Sanofi
Speakers' Bureau - Clinical Care Options/NCCN; Onclive; Physicans' Education Resource
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst)
Other Relationship - AstraZeneca; Boehringer Ingelheim
 
Solange Peters
Honoraria - AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Novartis; Pfizer; Regeneron; Roche/Genentech
Travel, Accommodations, Expenses - Roche
 
Luke T. Nordquist
No Relationships to Disclose
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - AstraZeneca; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Lilly; Merck Serono; Merck Serono; Novartis; Novartis; Ono Pharmaceutical; Pfizer; Pfizer; Sumitomo Dainippon; Sumitomo Dainippon; Taiho Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Abbvie (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Boehringer Ingelheim (Inst); Novartis; Novartis; Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); PAREXEL (Inst); PAREXEL (Inst); Pfizer (Inst); Pfizer (Inst); Quintiles (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Paulo Andre Miranda
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
 
Qin Wang
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
 
Mark A. Socinski
Honoraria - AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech
Consulting or Advisory Role - Genentech
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech
Research Funding - Genentech; Pfizer (Inst)